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Abstract
BK virus (BKV) is an opportunistic pathogen in those with impaired immunity. Viral replication is generally asymptomatic
but is able to induce cytopathic alterations in renal cells. If BKV infection is left untreated, it leads to BKV-associated
nephropathy (BKVAN) and graft loss. There is scarce experience in the management of BKV infection in kidney trans-
plant recipients living with HIV. We report the successful treatment of BKVAN in an HIV-positive kidney transplant
recipient who experienced BKV replication in the immediate post-transplantation period. A change in therapy from
calcineurin inhibitor to sirolimus, steroid withdrawal and a short course of an immunomodulatory agent (leflunomide)
controlled BKV viremia in the absence of drug side-effects or impairment of graft function.
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Introduction
Kidney transplantation is a safe and effective option
for end-stage renal disease (ESRD) in human
immunodeficiency virus (HIV)-positive kidney trans-
plant (KT) recipients.1–4 It has been associated with a
better outcome compared to dialysis treatment.
However, the use of antirejection agents exposes this
vulnerable population to multiple opportunistic infec-
tions. BK virus (BKV) is a pathogen frequently
encountered after kidney transplantation. The manifes-
tations are heterogeneous and vary from a sub-clinical
viruria to BKV-associated nephropathy (BKVAN).
Treatment of BKV infection remains undetermined
and consists primarily of the reduction of immunosup-
pression.5 This strategy has been offset by a higher risk
of graft rejections.6,7 In the last decade, sirolimus (SIR)
and everolimus, two immunosuppressive agents with
multiple pleiotropic activities, have been shown to be
effective against BKV in few retrospective8–11 and pro-
spective studies12,13 limited to kidney transplantation.
Given the scarce experience about the management of
BKV infection in people living with HIV, we report our
therapeutic strategy in controlling sustained BKV rep-
lication in an HIV-positive KT recipient.
Case presentation
A 45-year-old Caucasian female with a diagnosis of
HIV-1 infection from 1995 progressed to end-stage
renal disease in March 2014. Renal failure was second-
ary to repeated episodes of acute pyelonephritis. She
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had never experienced an AIDS-defining illness and the
nadir of her CD4þ T-cell count was 386 cells/mm3 in
February 1998. Antiretroviral therapy (ART) was
started soon after this drop in CD4 cell count.
After one year of peritoneal dialysis, she received a
deceased donor KT in March 2015. Before transplan-
tation, her HIV viral load (VL) was undetectable and
CD4þ T-cell count was 1146 cells/mm3. Her ART con-
sisted of lamivudine/raltegravir/rilpivirine (3TC/RAL/
RPV). The patient received basiliximab and steroid
as induction therapy and tacrolimus (TAC) and
prednisone as maintenance therapy. She had
immediate allograft function and was discharged with
a creatinine of 1mg/dl (eGFR,14 63ml/min) on postop-
erative day 14. After transplantation, ART was
changed to raltegravir/maraviroc/rilpivirine (RAL/
MVC/RPV). Valganciclovir and co-trimoxazole were
used as prophylaxis for cytomegalovirus and pneumo-
cystis infections, respectively.
Mean TAC trough level was 10.1mg/dl during the
first two months. At the end of the first month after
transplantation, measurement of BK viral load by real-
time polymerase chain reaction (BKV ELITe MGBVR
Kit) revealed a viruria and viremia of 5.4 log10 and
2.5 log10 copies/mL, respectively. In December 2015,
a progressive and concerning increase of viruria (8.4
log10 copies/mL) and viremia (3.8 log10 copies/mL)
prompted early steroid withdrawal in order to enhance
host immunocompetence against BKV. In March 2016,
graft biopsy was performed for a progressive decline in
renal function (serum creatinine 1.27 vs. 1mg/dl). It
revealed viral cytogenic alterations suggestive of
BKVAN. Microscopic evaluation showed regional
interstitial inflammation with a prevalence of mononu-
cleated cells and several tubular epithelial cells with
intranuclear viral inclusion bodies typical of viral infec-
tion (Figure 1). In some tubules, the proliferation of
BKV manifested as tubulitis. SV40 T-antigen antibody
provided negative results. Lack of endarteritis, negative
staining for C4d on graft biopsy and absence of blood
donor-specific antibodies (DSA) excluded the diagnosis
of graft rejection. No signs of calcineurin toxicity were
found in the biopsy specimen.
Based on these findings, TAC was switched to SIR
for its antiproliferative proprieties in April 2016. SIR
trough level was maintained between 5 and 8 ng/dl. In
order to favor the resolution of BKV, she started leflu-
nomide at a standard dose of 40mg daily, but the drug
was prematurely discontinued due to severe pancyto-
penia. After an early BK peak viruria of 10 log10
copies/mL and viremia of 6.3 log10 copies/mL, serum
viral load declined progressively to about 2.0 log10 in
2017 and remained constantly stable until July 2018
despite a normal CD4þ T-cell count (Figure 2).
At the end of the follow-up, her creatinine level set-
tled to 1.5mg/dl corresponding to an eGFR14 of
Figure 1. Masson’s trichrome stain reveals regional interstitial inflammation with prevalence of mononuclear cells (*). Tubular injury
is characterized by tubular desquamation, flattened epithelial lining and mild tubulitis (full arrow). Cytopathic effects of polyomavirus
infection are seen prevalently in tubular cells. Nuclei of infected tubular cells are diffusely enlarged and often have a surrounding halo.
Some nuclei are characterized by a central irregular inclusion body surrounded by a halo (empty arrow), others by finely granular
alterations (arrowhead).
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38ml/min. Urinalysis was negative as was the detection
of DSA. After 1.5 years from the introduction of SIR
(mean trough level of 7.23mg/dl), no episodes of acute
allograft rejection or SIR-associated side effects had
occurred in our patient.
Discussion
With this case report we present our successful experi-
ence in controlling BKV replication in an HIV-positive
KT recipient with a suppressed HIVVL. BKV infection
was responsible for the development of BKVAN and
graft impairment in the early post-transplantation
period. The infection was managed with a combined
strategy including conversion from TAC to SIR, ste-
roid withdrawal and administration of an immuno-
modulatory drug (leflunomide). We decided to use
SIR given its clear antiviral properties against some
pathogens (i.e., CMV, HHV-8) commonly encountered
after solid organ transplantation. After these therapeu-
tic changes, the profile of BKV replication
progressively improved until reaching a clinically insig-
nificant VL and eliminating the risk of graft loss due to
the BKV-related tubulointerstitial damage. Given the
multiple therapeutic changes, we are unable to separate
clearly the beneficial effects of every single intervention
on the resolution of BKV infection. Likely, leflunomide
had little or no effect in controlling BKV replication
because exposure to this drug was too short to modu-
late the antiviral response of the host; furthermore, it is
still unclear if this drug is really effective in the treat-
ment of BKV infection.15
Hence, reduction of immunosuppression with ste-
roid withdrawal, conversion to a weaker immunosup-
pressive agent with antiproliferative proprieties and
likely administration of an immunomodulatory agent
with antiviral activity had a pivotal role in the resolu-
tion of BKVAN.
SIR, with its immunosuppressive and antiviral activ-
ity, is theoretically the most suitable agent to use in KT
recipients with BKV infections. Liacini et al.16 demon-
strated that SIR is able to impair intracellular signaling
Figure 2. Schematic representation of antiretroviral and immunosuppressive therapies, serum creatinine (mg/dl), and BKV viremia
and viruria (copies/ml) after kidney transplantation.
MVC: maraviroc; RAL: raltegravir; RPV: rilpivirine.
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pathways activated by BKV once the virus infects the
cells. Recently, two in vivo studies have shown that
rapamycin can modulate memory CD8þ T-cell differ-
entiation in mice.17,18 Surprisingly, this immunosup-
pressive agent improves both quantity and quality of
memory CD8þ T cells stimulated by pathogens. SIR
also possesses anti-HIV viral activity. Heredia et al19
documented, in an elegant in vitro study, that SIR
reduced the expression of CCR5, a co-receptor used
by HIV-1 to enter and infect CD4-expressing immune
cells. SIR is therefore able to control HIV replication in
both HIV-positive liver20 and KT21 recipients and to
reduce the level of persistent cell-associated HIV DNA
in HIV-positive KT recipients.22
In our patient, the beneficial antiproliferative effects
of SIR were achieved without reaching toxic blood
levels. The immunosoppressive agent was well tolerat-
ed, and no side effects such as heavy proteinuria,
edema, dyslipidemia, oral aphthous ulcers, and pneu-
monitis developed during the follow-up period. This
strategy also enabled the avoidance of graft rejection,
a frequent and problematic complication in HIV-
positive KT recipients.23 However, the use of SIR has
to be balanced against an alarming risk of worse long-
term graft and patient outcomes compared to the stan-
dard immunosuppressive therapy including calcineurin
inhibitors.24–26 Although we were aware of this risk, we
decided to maintain the same immunosuppression
because of the persistent low-level replication of BKV
despite a suppressed HIV VL and a normal CD4þ T-
cell count.
Conclusion
Reduction of immunosuppression, conversion from
calcineurin inhibitors to SIR and, likely, the use of
immunomodulatory agent should be taken into consid-
eration in HIV-positive KT recipients with BKV repli-
cation, as this infection is a notable cause of graft
failure. In this case, conversion to SIR was safe and
not associated with renal rejection or drug side-effects.
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